ReviewJournal of bone metabolism2015
Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea.
Review in Journal of bone metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Non-pyroptotic caspase-11 activity regulates osteoclastogenesis and pathological bone loss.Cell death and differentiation · 2026Article
- Effect of Severe Bowing in Bisphosphonate-Related Atypical Femoral Fracture.Clinics in orthopedic surgery · 2025Article
- Arcyriaflavin A Alleviates Osteoporosis by Suppressing RANKL-Induced Osteoclastogenesis.International journal of molecular sciences · 2025Article
- Prolonged Impact of Bisphosphonates and Glucocorticoids on Bone Mechanical Properties.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effect of clodronate on gene expression in the peripheral blood of horses.Journal of veterinary pharmacology and therapeutics · 2024Article
- A Vitronectin-Derived Peptide Restores Ovariectomy-Induced Bone Loss by Dual Regulation of Bone Remodeling.Tissue engineering and regenerative medicine · 2022Article
- Zoledronic Acid Ameliorates the Bone Turnover Activity and Periprosthetic Bone Preservation in Cementless Total Hip Arthroplasty.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies.The Saudi dental journal · 2022Review
- Detection and residence time of bisphosphonates in bone of horses.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022Article
- Article
- Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making.Journal of clinical medicine · 2021Review
- Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment.Journal of bone metabolism · 2019Review
- Article
- Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.Journal of Korean medical science · 2018Article
- Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).Dentistry journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates have been widely used in the treatment of osteoporosis with robust data from many placebo-controlled trials demonstrating its efficacy in fracture risk reduction over 3 to 5 years of treatment. Although bisphosphonates are generally safe and well tolerated, concerns have emerged about the adverse effects related to its long-term use, including osteonecrosis of the jaw and atypical femur fractures. Because bisphosphonates are incorporated into the skeleton and continue to exert an anti-resorptive effect for a period of time after the discontinuation of drugs, the concept of a "drug holiday" has emerged, whereby the risk of adverse effects might be decreased while the patient still benefits from anti-fracture efficacy. As randomized clinical trial evidence is not yet available on who may qualify for a drug holiday, there is considerable controversy regarding the selection of candidates for the drug holiday and monitoring during a drug holiday, both of which should be based on individual assessments of risk and benefit. This statement will provide suggestions for clinicians in South Korea on the identification of possible candidates and monitoring during a bisphosphonate drug holiday.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.